THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
MyHealthChecked plc
("MyHealthChecked" or the "Company")
AGM Statement
MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, provides an update to shareholders ahead of its Annual General Meeting ("AGM") today at The Maltings, East Tyndall Street, Cardiff, CF24 5EA at 10.00 a.m.
Chairman's AGM statement
Earlier this month we were delighted to announce a record year in terms of revenues, with the business not only performing financially, but also in terms of providing outstanding customer service and delivery. We started the new financial year in a much stronger position, and I am pleased to report that we have seen this good momentum continue into the new financial year.
The first half of the year saw us continue to support the deployment of our COVID-19 PCR nasal swab test kit for at-home use for the UK's top two high street pharmacy retailers. At the same time, we prepared for the launch of five new at-home cheek swab DNA wellness tests, all of which were made available to customers earlier this month. These wellness tests cover Intolerances & Sensitivities, Weight Management, Heart Profile, Vitamins & Minerals and Glucose Management. They are priced at £54 and are available on our website: https://myhealthchecked.com
Ahead of this launch, trading in the first six months of the current year has been stronger than expected and is ahead of budget. A more comprehensive trading update for the six months ended 30 June 2022 will be provided in mid-July.
We expect to publish our unaudited half-year results in September and look forward to updating shareholders on initial commercial progress of our new portfolio of wellness tests then.
For further information contact:
| MyHealthChecked plc | ||
| Penny McCormick, Chief Executive Officer | via Walbrook PR | |
| | | |
| SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | |
| Neil Baldwin | | |
| | | |
| Oberon Capital Ltd (Broker) | Tel: +44 (0)203 179 5344 | |
| Mike Seabrook | ||
| | | |
| Walbrook PR Ltd (Media & IR) | Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44(0)7980 541 893 / +44(0) 7407 804 654 | |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
